Status:
COMPLETED
Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Myovant Sciences GmbH
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
This clinical trial studies a digital platform, the supportive therapy in androgen deprivation (STAND-T), in achieving equity for men undergoing treatment with androgen deprivation therapy for prostat...
Detailed Description
PRIMARY OBJECTIVE: I. To assess study feasibility of the STAND-T program at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) and Zuckerberg San Francisco General Hospital and Trauma Cente...
Eligibility Criteria
Inclusion
- Age \>18 years
- Ability to understand study procedures and to comply with them for the entire length of the study
- Ability of individual or legal guardian/representative to understand an informed consent document and the willingness to sign it
- Adenocarcinoma of the prostate
- Current or planned anti-androgen therapy (ADT) (oral or injection) with gonadotropin-releasing hormone (GnRH) antagonist or luteinizing hormone releasing hormone (LHRH) agonist
- Life expectancy duration of 6 months or longer from date of study consent
- Prior and concurrent radiation is allowed
- Treatment with concurrent androgen signaling inhibitors is allowed
- \< 75 minutes/week of vigorous aerobic exercise based on Godin survey or \< 2 days per week of vigorous activity
Exclusion
- Contraindication to any study-related procedure or assessment
- Planned surgery/chemotherapy/immunotherapy/parp inhibitor treatment during the study period
- Prior and concurrent investigational therapies
- Unable to read/speak English
- Unable to access the Internet
- Has seen an exercise counselor in the past 6 months for prostate or cardiovascular health
- Has seen a dietary counselor in the past 6 months for prostate or cardiovascular health
Key Trial Info
Start Date :
March 8 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2023
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT05324098
Start Date
March 8 2022
End Date
July 31 2023
Last Update
June 10 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Zuckerberg San Francisco General Hospital
San Francisco, California, United States, 94110
2
University of California, San Francisco
San Francisco, California, United States, 94142